Intra-Arterial Treatment Effective With Extracranial Carotid Disease

Share this content:
Intra-Arterial Treatment Effective With Extracranial Carotid Disease
Intra-Arterial Treatment Effective With Extracranial Carotid Disease

THURSDAY, June 1, 2017 (HealthDay News) -- Acute intra-arterial treatment (IAT) seems to be as effective for patients with acute ischemic stroke caused by intracranial proximal occlusion with, versus those without, extracranial carotid disease (ECD), according to research published online May 23 in the Annals of Internal Medicine.

Olvert A. Berkhemer, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues conducted a prespecified subgroup analysis of a randomized clinical trial of endovascular treatment for intracranial proximal anterior circulation occlusion in 16 hospitals in the Netherlands. Participants received either IAT or no IAT.

The researchers found that the functional outcome was associated with an adjusted common odds ratio (acOR) of 1.67 (95 percent confidence interval [CI], 1.21 to 2.30) in favor of the intervention. In the prespecified subgroup of patients with ECD, the acOR was 3.1 (95 percent CI, 1.7 to 5.8), compared to 1.3 (95 percent CI, 0.9 to 1.9) in patients presenting without ECD (P for interaction = 0.07).

"Intra-arterial treatment may be at least as effective in patients with ECD as in those without ECD, and it should not be withheld in these complex patients with acute ischemic stroke," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including AngioCare, Medtronic/Covidien/EV3, MEDAC/LAMEPRO, Penumbra, Stryker, and Top Medical/Concentric, all of which partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Cracks Down on Kratom Products

FDA Cracks Down on Kratom Products

Missouri-based Divinity Products Distribution will recall and destroy kratom-containing products

Kurtosis Diffusion-Weighted Imaging Helps ID Breast Lesions

Kurtosis Diffusion-Weighted Imaging Helps ID Breast Lesions

Radiomics feature model reduced false positives, with benefit seen for BI-RADS 4a, 4b lesions

is free, fast, and customized just for you!

Already a member?

Sign In Now »